Kiniksa Pharmaceuticals International (KNSA) Net Equity Issued and Repurchased (2018 - 2020)

Kiniksa Pharmaceuticals International's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $118.1 million for Q3 2020.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $118.1 million in Q3 2020, while the trailing twelve-month figure through Dec 2020 was $118.1 million (up 143.08% YoY) and the FY2020 annual result came in at $165.7 million, up 241.03% from the prior year.
• Net Equity Issued and Repurchased was $118.1 million for Q3 2020 at Kiniksa Pharmaceuticals International, up from $48.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $190.8 million in Q1 2018 and bottomed at -$31.6 million in Q2 2018.
• A 3-year average of $71.5 million and a median of $48.6 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 74.53% in 2019, while the deepest fall reached 74.53% in 2019.
• Kiniksa Pharmaceuticals International's Net Equity Issued and Repurchased stood at $31.6 million in 2018, then soared by 53.64% to $48.6 million in 2019, then jumped by 143.08% to $118.1 million in 2020.
• Business Quant data shows KNSA's Net Equity Issued and Repurchased at $118.1 million in Q3 2020, $48.6 million in Q1 2019, and $31.6 million in Q4 2018.